Vietnam to approve remdesivir for COVID-19 treatment - state media | Inquirer News

Vietnam to approve remdesivir for COVID-19 treatment – state media

/ 04:28 PM August 03, 2021

remdesivir

 A laboratory technician shows Remdesivir, a drug used in the treatment of the coronavirus disease (COVID-19), at Eva Pharma facility in Cairo, Egypt June 1, 2021. REUTERS FILE PHOTO

HANOI — Vietnam is set to approve the use of Gilead Sciences Inc’s antiviral drug remdesivir for the treatment of patients who have contracted the coronavirus, state media reported on Tuesday.

The Southeast Asian country successfully contained COVID-19 for much of the pandemic, but has seen a spike in infections and hospitalizations since an outbreak which emerged in late April.

ADVERTISEMENT

After receiving donated supplies of remdesivir, Vietnam has already been using the drug for COVID-19 treatment in some health facilities, the state-run VTC newspaper cited deputy health minister Nguyen Truong Son.

FEATURED STORIES

“The ministry is studying the inclusion of remdesivir in the treatment regimen and will approve the use of remdesivir in COVID-19 treatment soon,” Son said.

Remdesivir has been approved for emergency use in severely-ill patients in countries such as the United States, India and South Korea, and has received full approval in Japan.

Vietnam is due to receive 500,000 remdesivir vials and is also considering approving favipiravir, a drug which has also been shown to be effective in countering COVID-19, the health ministry said in an earlier statement.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: Health, remdesivir, Vietnam

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.